On September 21, Nuocheng Jianhua Science and Technology Innovation Board was officially listed, becoming the fifth "A+H" listed unprofitable innovative drug company
.
The company's IPO raised 4 billion yuan, and the funds raised will be used for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, information construction projects and supplementary working capital
.
It is worth noting that in addition to Nuocheng Jianhua, there is also a pharmaceutical stock listed
today.
It is understood that on September 5, Enwei Pharmaceutical's initial public offering of shares and listing on the ChiNext Board online roadshow was successfully held
at the panoramic roadshow.
According to the listing announcement, the company's shares will be listed
on the Growth Enterprise Market of the Shenzhen Stock Exchange on September 21, 2022.
The company's stock code is 301331, the issue price is 29.
8 yuan / share, and the price-to-earnings ratio is 24.
72 times
.
According to the data, Enwei Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs and other fields
.
Among them, in the field of gynecological products has been deeply cultivated for many years, according to the data, from 2017 to 2021, the core product "Jieer Yin Lotion" in the field of gynecological inflammation of Chinese proprietary medicines in Chinese urban retail pharmacies has continuously ranked in the forefront
.
It is worth mentioning that in addition to the external lotion of gynecology, Enwei Pharmaceutical has not disconnected the dosage forms such as ointments, suppositories, effervescent tablets and disinfection products such as bacteriostatic lotion, and intends to develop gynecological internal medicine series products in independent research and development, joint research and development, purchase of varieties and other ways, and constantly maintain and further enhance the company's advantages
in the field of domestic gynecological products.
In addition, Enwei Pharmaceutical is also constantly expanding product extension by giving full play to its brand advantages and sales channel advantages, actively developing pediatric drugs and respiratory system drugs, and forming a diversified product group
covering reproductive system, digestive system, respiratory system and tonic fields.
At present, the company has 17 exclusive varieties, including Jie'er Yin Lotion, Jie'er Yin Ointment, Jie'er Yin Effervescent Tablets, Shanmai Jian Spleen Oral Liquid, Qingjing Capsules, Danqi Tongmai Granules, etc.
, and the total sales revenue of exclusive varieties during the reporting period accounts for more than
50% of the main business income.
Benefiting from the diversification of products and other influences, the company's performance has also begun to grow
continuously.
It is understood that from 2019 to 2021, Enwei Pharmaceutical's revenue will be 620.
7 million, 634.
2 million and 679.
7 million, respectively, and the revenue in 2021 will increase by 7.
18% year-on-year; Net profit was 91.
58 million, 105.
2 million and 101.
7 million
, respectively.
Enwei Pharmaceutical expects to achieve operating income of about 460 million yuan to 500 million yuan from January to September 2022, an increase of about -5.
49% to 2.
73% year-on-year; Net profit was approximately CNY 56 million to CNY 66 million, an increase of approximately -14.
48% year-on-year to 0.
79%.
Industry analysts believe that under a series of policy guidance and the trend of upgrading the consumption of traditional Chinese medicine, the traditional Chinese medicine industry has long-term investment value
.
Especially in the first half of this year, under the background of the successive introduction of favorable policies to support the development of traditional Chinese medicine, the Chinese medicine sector has a strong upward momentum, in this context, the industry can pay more attention to
it after the listing of Enwei Pharmaceutical.
